Estrella Immunopharma, Inc. financial data

Symbol
ESLA, ESLAW on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
5858 Horton Street, Suite 370, Emeryville, California
Fiscal year end
June 30
Former names
TradeUP Acquisition Corp. (to 9/20/2023)
Latest financial report
Q1 2024 - May 15, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 23.8 % -95.6%
Debt-to-equity 174 %
Return On Equity -86.6 % -151%
Return On Assets -28.4 % +10.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 36.4 M shares +1461%
Common Stock, Shares, Outstanding 36.5 M shares +2474%
Entity Public Float 58.5 M USD
Common Stock, Value, Issued 3.66 K USD +2478%
Weighted Average Number of Shares Outstanding, Basic 35.5 M shares +10431%
Weighted Average Number of Shares Outstanding, Diluted 35.6 M shares +10453%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 25 K USD -99%
General and Administrative Expense 445 K USD +278%
Operating Income (Loss) -3.53 M USD +59.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -513 K USD +31%
Income Tax Expense (Benefit) 121 K USD
Net Income (Loss) Attributable to Parent -3.44 M USD +60.7%
Earnings Per Share, Basic -0.01 USD/shares +99.9%
Earnings Per Share, Diluted -0.01 USD/shares +99.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.73 M USD +15985%
Accounts Receivable, after Allowance for Credit Loss, Current 273 K USD
Assets, Current 8.63 M USD +10443%
Operating Lease, Right-of-Use Asset 0 USD
Assets 8.63 M USD -11.7%
Accrued Liabilities, Current 167 K USD
Liabilities, Current 138 K USD -88.6%
Deferred Income Tax Liabilities, Net 8.37 K USD
Other Liabilities, Noncurrent 12.7 K USD
Liabilities 138 K USD -95%
Retained Earnings (Accumulated Deficit) -15.5 M USD -515%
Stockholders' Equity Attributable to Parent 8.49 M USD
Liabilities and Equity 8.63 M USD -11.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -275 K USD +75%
Net Cash Provided by (Used in) Financing Activities 20 M USD
Net Cash Provided by (Used in) Investing Activities -112 K USD
Common Stock, Shares Authorized 250 M shares +733%
Common Stock, Shares, Issued 36.6 M shares +2479%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -11.4 K USD +92.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.73 M USD +77.8%
Deferred Tax Assets, Valuation Allowance 344 K USD +119%
Deferred Tax Assets, Gross 263 K USD +405%
Deferred Income Tax Expense (Benefit) -21.7 K USD
Deferred Tax Assets, Operating Loss Carryforwards 0 USD -100%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1 M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 24.1 M USD
Preferred Stock, Shares Outstanding 0 shares
Current State and Local Tax Expense (Benefit) 0 USD
Current Federal Tax Expense (Benefit) 113 K USD
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 102 K USD
Deferred State and Local Income Tax Expense (Benefit) 0 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%